AMLX Amylyx Pharmaceuticals
Amylyx Pharmaceuticals earnings company data as of 4:45 AM ET 11/1
Scheduled
1 period, newest first, nothing reported yet. Each row shows EPS above revenue.
| Period | Date | Metric | Estimate | Actual | Result |
|---|---|---|---|---|---|
| FY2026 Q3 | 5 Nov | EPS | -0.37 | — | — |
| Rev | $41.6K | — | — |
Insider trades
Open-market buys and sales by AMLX's executives, directors and 10% owners in the last 12 months, from their Form 4s
- $152K bought by 1 insider
- None no sales outside a trading plan
- $1.4M sold by 2 insiders under 10b5-1 plans
-
George M Milne Jr. DirectorPlanned sale$831K 30,000 shares at $27.70 3.7% of stakeTraded Oct 5 Filed Oct 7
-
Gina Mazzariello Chief Legal OfficerPlanned sale$539K 30,000 shares at $17.96 14% of stakeTraded Jul 9–10 Filed Jul 13
-
Karen Firestone DirectorBuy$51K 3,800 shares at $13.51 +6% to stakeTraded May 21 Filed May 26
-
Karen Firestone DirectorBuy$101K 8,100 shares at $12.45 +15% to stakeTraded Dec 23, 2025 Filed Dec 23, 2025
Also filed in the last 12 months, not counted as buying or selling: 28 sales to cover taxes, 10 stock grants, 6 option exercises, and 1 gift.
SEC filings
Recent issuer filings from EDGAR, 16 shown.
| Filed | Form | Detail | Links |
|---|---|---|---|
| 8-K | 1.01 | Filing Doc | |
| 424B5 | Filing Doc | ||
| 8-K | 1.01,9.01 | Filing Doc | |
| 8-K | 7.01,8.01,9.01 | Filing Doc | |
| 8-K | 8.01,9.01 | Filing Doc | |
| 424B5 | Filing Doc | ||
| 8-K | 2.02,9.01 | Filing Doc | |
| 10-Q | Filing Doc | ||
| 8-K | 5.07 | Filing Doc | |
| SCHEDULE 13G/A | — | Filing Doc | |
| 8-K | 2.02,9.01 | Filing Doc | |
| 10-Q | Filing Doc | ||
| DEF 14A | Filing Doc | ||
| DEFA14A | Filing Doc | ||
| SCHEDULE 13G/A | — | Filing Doc | |
| 8-K | 7.01,9.01 | Filing Doc |
No filings match this filter.
Estimates are consensus figures; SEC filings remain the official record. Not investment advice.